CoChat

MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy

Rayburn, Elizabeth, Zhang, Ruiwen, He, Jie, Wang, Hui · 2005 · Current Cancer Drug Targets

The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.

Abstract

The human homologue of the mouse double minute 2 (MDM2) oncogene is overexpressed in more than forty different types of malignancies, including solid tumors, sarcomas and leukemias. Because of its prevalent expression and its interactions with p53 and other signaling molecules, MDM2 plays a central role in cancer development and progression. The expression of this oncoprotein is being studied by researchers world-wide, and the amount of data published about it is increasing exponentially. Although there are some conflicting data about the effects of MDM2 expression in individual cancers, the overall evidence is convincing, indicating that increased MDM2 expression is related to a worse clinical prognosis. There is an increased likelihood of distant metastases, as well as a decreased response to therapeutic intervention in MDM2-positive cancers. MDM2 may also serve as a diagnostic marker, not only for cancer stage, but to differentiate between similar cancers. MDM2 may also be associated with drug resistance in cancer chemotherapy. These findings make studying the oncoprotein necessary to aid in our understanding of cancer development, to identify novel cancer drug targets, and to increase the efficacy of cancer therapy.

Overview

Integrity signals

Registry

Crossref · 10.2174/1568009053332636

Cites

182 of 182 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 182 references

Cited by

See all 265

Metadata

Authors
Rayburn, E., Zhang, R., He, J., & Wang, H.
Affiliations
University of Alabama at Birmingham (US)
Venue
Current Cancer Drug Targets
Published
2005-02-01
Volume
5
Issue
1
Pages
27-41
ISSN
1568-0096 (ISSN-L)
OpenAlex
W2107368531
Cited by
265
References
172
Citations by year
2026: 3 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 10 · 2021: 13 · 2020: 15 · 2019: 18 · 2018: 12 · 2017: 24 · 2016: 10 · 2015: 20 · 2014: 19 · 2013: 13 · 2012: 12
FWCI
4.97
Type
journal article
Language
en
Open access
closed
Locations
  • Current Cancer Drug Targets (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01ca080698-04)
  • National Cancer Institute (R01CA112029, R01 CA 80698)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
MDM2, p53, oncogene overexpression, prognostic factors, metastasis, chemoresistance, diagnostic biomarkers, cancer drug targets, sarcoma, leukemia, solid tumors, tumor progression
MeSH terms
Animals, Antineoplastic Agents, Humans, Neoplasm Metastasis, Neoplasms, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy. https://app.cochat.ai/papers/10.2174/1568009053332636
The paper
Rayburn, E., Zhang, R., He, J., & Wang, H. (2005). MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy. Current Cancer Drug Targets. https://doi.org/10.2174/1568009053332636

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.